GUILFORD, Conn., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc., creator of the Swoop® Point-of-Care MRI System™ for imaging of the brain, today announced the acceptance of twelve abstracts related to the Swoop® system to be presented at the prestigious International Society for Magnetic Resonance in Medicine (ISMRM) and International Society of MR Radiologist and Technologists (ISMRT) annual meeting. The annual ISMRM and ISMRT meeting, taking place this year in Toronto June 3–8, highlights current and emerging technological advances in magnetic resonance imaging and medicine worldwide.

The research in these abstracts was conducted by leading teams in the field of MRI at the University of Pennsylvania (UPenn), University of British Columbia, King’s College London, New York University (NYU), Illinois Institute of Technology, National Institute of Standards and Technology (NIST), Cardiff University, and the Icahn School of Medicine at Mount Sinai. The scope of the cutting-edge research covers a wide range of topics, including phase-sensitive reconstruction, diffusion-tensor imaging, and super-resolution imaging. Researchers will present the abstract Tensors and Tracts at 64mT as a “Power Pitch,” which highlights the most exciting abstracts of the annual meeting.

Hyperfine developed the Swoop® system by focusing on enhancing patient outcomes. With the portable, ultra-low-field Swoop® system, Hyperfine aims to redefine the neuroimaging workflow by bringing brain imaging to the patient’s bedside. Research such as that highlighted at ISMRM and ISMRT will help to further support the development of these efforts and help strengthen the already robust Hyperfine IP portfolio.

“The previous work of these teams has significantly contributed to the science of ultra-low-field MRI and helped bring this innovative technology to the patient’s bedside. The basic and clinical research showcased at this year's ISMRM and ISMRT meeting offers a glimpse of the potential of these advancements to further the Hyperfine mission of revolutionizing patient care through transformational, accessible, clinically relevant diagnostic imaging across multiple clinical uses and sites of care,” stated Khan Siddiqui, MD, chief medical officer and chief strategy officer of Hyperfine.

For more information about the Swoop® Portable MR Imaging System™, please visit http://www.hyperfine.io.

About Hyperfine and the Swoop® Portable MR Imaging System™
Hyperfine (NASDAQ: HYPR) is the groundbreaking medical technology company that created Swoop®, the world’s first FDA-cleared portable magnetic resonance imaging (MRI) system capable of providing neuroimaging at the point of care. The mission of Hyperfine is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging, and data solutions. Founded by Dr. Johnathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside. For more information, visit hyperfine.io.

Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Hyperfine’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations about Hyperfine’s financial and operating results, the benefits of Hyperfine’s products and services, and Hyperfine’s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of Hyperfine’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of Hyperfine product development and commercialization activities, including the degree that Swoop® is accepted and used by healthcare professionals; the impact of COVID-19 on Hyperfine’s business; the inability to maintain the listing of Hyperfine’s Class A common stock on the Nasdaq; the inability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition and Hyperfine’s ability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of Hyperfine to raise financing in the future; the inability of Hyperfine to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of Hyperfine to identify, in-license or acquire additional technology; the inability of Hyperfine to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of Hyperfine to compete with other companies currently marketing or engaged in the development of products and services that Hyperfine is currently marketing or developing; the size and growth potential of the markets for Hyperfine’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Hyperfine’s products and services and reimbursement for medical procedures conducted using Hyperfine’s products and services; Hyperfine’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; Hyperfine’s financial performance; and other risks and uncertainties indicated from time to time in Hyperfine’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. Hyperfine cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. Hyperfine does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Media Contact
Annika Parrish
Health+Commerce
annika@healthandcommerce.com

Investor Contact
Marissa Bych
Gilmartin Group LLC
marissa@gilmartinir.com